🔗 Share this article

An underground economy for unlicensed weight-loss medications is being driven by TikTok fitness influencers and vendors on messaging platforms, according to new investigations.

Investigational Drug Gaining Popularity Via Social Media

Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its alleged fat-burning properties. Viewers are encouraged to contact these profiles directly for source information, while also obtaining discount codes.

Thriving Trade on Messaging Platforms

Separately, a robust trade exists on Telegram, where groups with thousands of members share comparison photos, administration instructions and claims of next-day UK delivery. Vendors market the substance there before redirecting buyers to WhatsApp for purchases.

Learning About The Experimental Drug

Retatrutide is an experimental injectable created by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help patients reduce up to 25% of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Medical Experts Voice Worries

However, doctors and chemists have cautions that the distribution of what is still an unlicensed medication in the United Kingdom is a cause for concern and could lead to individuals administering products of unknown origin.

Several experts said the popularity for the experimental drug could be linked to the rising cost of licensed weight loss products such as Mounjaro.

Regulatory Status and Implementation

Selling the unapproved drug on TikTok or messaging apps is prohibited in the United Kingdom, as it is an unapproved medication that cannot be marketed or distributed for human use under the British medical regulations.

Some influencers try to circumvent the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and distribution can still breach medicines, marketing, and customer regulations, potentially leading to fines, legal action or imprisonment.

Platform Response and Content Elimination

Based on the social media company, the platform has taken down violative content and prohibited associated keywords and search suggestions. The company said it was committed to maintaining the platform secure and allocating resources in enhancing compliance measures.

Digital Trading Operations

Research also discovered groups with up to nine thousand participants marketing the experimental drug using the platform's integrated discovery tool, which operates like a online catalog. Entering “retatrutide” immediately brings up channels with thousands of members, populated with photos of weight loss, glowing reviews and step-by-step instructions for mixing or administering at residence.

After minutes of joining one community, a seller shared WhatsApp details, where the majority of transactions occur. The vendor sent an guidebook and promised delivery within 48 hours. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one inquired about weight, health issues or past usage.

Item Information and Costs

Within these groups, posts show black plastic parcels with Royal Mail labels, stating to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at residence with purified liquid, or pre-filled pens usually priced at £160 for 20mg. When asked how long a injector should be used, sellers give contradictory answers varying between a few weeks to “depends on your body”.

Service Oversight and Safety Actions

A representative for the messaging service stated it actively monitored dangerous material on its service including content that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Warnings

“People are administering substances they can’t verify. Even if the research behind this drug is valid, these digital products may not include what they claim,” stated Jason Murphy, the director of pharmacy at Chemist4U.

A medical professional of an online medical service connected the surge in demand to recent price rises for approved weight-loss medications such as Mounjaro. “With costs increasing, patients are using social media. But fake injections are highly risky. You cannot know what’s inside or whether the conditions they were made in was sterile,” she said.

Her team has already encountered individuals harmed by personal administration from unconfirmed sources. “We recognize the frustration, but buying from Telegram or WhatsApp is taking chances with your health,” said Wyllie. “These substances could be contaminated or incorrectly dosed.”

Manufacturer Statement

A representative from the pharmaceutical company stated retatrutide was in phase 3 research studies and had not been reviewed or approved by any regulatory agency anywhere in the world. “Consequently at this point no one can sell [it] for personal consumption,” they explained, noting that any item “falsely representing itself as a company experimental product not yet authorized … may expose users to possibly significant health risks”.